The recent 2023 ESH guidelines for the management of arterial hypertension clearly support the use of a RAS inhibitor as a common agent of the general combination, while the five major drug classes were recommended as first-line agents for the treatment of hypertension, i.e., angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers, calcium channel blockers, Thiazide/Thiazide-like diuretics, and Beta-blockers (class of recommendation: I, level of evidence A) [22,23]. This evidence concerns the gene ACE and Hypertension.